Skip to main content
Deepa Jagadeesh, MD, Oncology, Cleveland, OH, Cleveland Clinic

DeepaJagadeeshMDMPH

Oncology Cleveland, OH

Cutaneous Lymphoma, Hematologic Oncology

Associate Staff, Taussig Cancer Institute, Cleveland Clinic

Dr. Jagadeesh is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Jagadeesh's full profile

Already have an account?

Education & Training

  • UMass Chan Medical School
    UMass Chan Medical SchoolFellowship, Hematology and Medical Oncology, 2009 - 2012
  • UMass Chan Medical School
    UMass Chan Medical SchoolResidency, Internal Medicine, 2005 - 2008
  • UMass Chan Medical School
    UMass Chan Medical SchoolInternship, Transitional Year, 2004 - 2005
  • J.J.M. Medical College
    J.J.M. Medical CollegeClass of 1996

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2012 - 2022
  • MA State Medical License
    MA State Medical License 2008 - 2012
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Effect of Bone Marrow CD34+Cells and T-cell Subsets on Clinical Outcomes After Myeloablative Allogeneic Hematopoietic Cell Transplantation  
    Deepa Jagadeesh, Matt Kalaycio, Brian Bolwell, Betty K Hamilton, Brian Hill, Brad Pohlman, Robert Dean, Navneet S Majhail, Sagar S Patel, Rabi Hanna, Aaron T Gerds, Ro..., Nature

Abstracts/Posters

  • Outcomes and Factors Impacting Use of Axicabtagene Ciloleucel in Refractory and Relapsed Large B-Cell Lymphoma: An Intent-to-Treat Analysis
    Deepa Jagadeesh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)
    Deepa Jagadeesh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Targeted Treatment and Survival Following Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and MDS in the Contemporary Era
    Deepa Jagadeesh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Response to brentuximab vedotin by CD30 expression: Results from five trials in PTCL, CTCL, and B-cell lymphomas. 
    2019 ASCO Annual Meeting - 6/1/2019
  • Phase I Trial of Carfilzomib + R-CHOP (CarR-CHOP) for Frontline Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Risk of Epstein-Barr-Associated Post-Transplant Lymphoproliferative Disorders Low in Solid Organ Transplant Patients
    Risk of Epstein-Barr-Associated Post-Transplant Lymphoproliferative Disorders Low in Solid Organ Transplant PatientsFebruary 11th, 2019
  • R-EPOCH May Extend Survival in Patients with Rare Forms of Diffuse Large B-cell Lymphoma
    R-EPOCH May Extend Survival in Patients with Rare Forms of Diffuse Large B-cell LymphomaMarch 11th, 2019
  • Stark County Woman Shares Story of Battle with Rare Cancer to Give Others Hope
    Stark County Woman Shares Story of Battle with Rare Cancer to Give Others HopeFebruary 29th, 2020
  • Join now to see all

Hospital Affiliations